The interaction of Poland’s transfer pricing rules and reimbursement law means the pharmaceutical industry is faced with complex compliance demands, explains Aneta Blazejewska-Gaczynska and Slawomir Buszko of Ernst & Young.
The material on this site is for financial institutions, professional investors and their professional advisers.
It is for information only. Please read our
Terms and Conditions
before using the site.
All material subject to strictly enforced copyright laws. ©2018
Euromoney Institutional Investor PLC.
For help please see our FAQ.